SecBot SecBot
8-K ·Filed Nov 9, 2026

XENE

Xenon Pharmaceuticals Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed7d 9h ago SEC0001193125-26-453521
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The December 2026 X-NOVA2 MDD topline data readout is the next major catalyst; positive results could de-risk the psychiatry pipeline and offset concerns from the voluntary enrollment pause. Monitor for FDA acceptance of the NDA and any update on the MDD/BPD pause.

DirectionNeutral
Confidencemedium
Horizonweeks

Drugs in focus

XENE drug pipeline →

azetukalner

◆ Mixed Named in this 8-K
Impact
Phase
Filed/NDA under FDA review
Time to market
If the FDA accepts the NDA for filing (expected mid-November 2026), a standard 10-month review would set a PDUFA target action date around mid-2027. The drug could potentially launch in the second half of 2027 if approved.
Next catalyst
None dated

What to watchThe next near-term catalyst is the FDA's 60-day filing acceptance decision on the azetukalner NDA, expected around mid-November 2026. If accepted, a PDUFA date (likely standard review, ~10 months, pointing to mid-2027) would be set. The Q3 2026 earnings call on Nov 9 may also provide updates on the psychiatry program pause and the X-TOLE3/X-ACKT epilepsy trials. The psychiatry safety overhang and the stock's 46% decline from its 52-week high mean the FDA filing acceptance and any clarity on the depression program restart timeline are the key swing factors.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$41.39
T+0 close · Nov 9, 2026 · via day close
Latest settled
+1.72%
T+1 · $42.10 · next T+5 in 6h
Vs SPY
+0.40%
α at T+1
Latest observation
−2.83%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $41.39entry
  2. T+1 · 6d ago +1.72%α +0.40% · $42.10
  3. T+4 · todayOpen
  4. T+5 · in 6h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xenon reported Q3 2026 results with a net loss of $110.4M, wider than the $90.9M loss in Q3 2025, driven by higher R&D spending. The key catalyst is the NDA submission for azetukalner in focal seizures and the upcoming X-NOVA2 MDD topline data readout in December 2026, though a voluntary pause on new enrollment in MDD/BPD studies introduces uncertainty.

Key Financial Metrics

EPS
−$1.11
Revenue
$0.00
est $0.00

Key Facts

  • NDA for azetukalner in focal seizures submitted to FDA in September 2026
  • Phase 3 X-NOVA2 MDD study enrollment completed; topline data expected December 2026
  • Voluntary pause on new patient enrollment in ongoing Phase 3 MDD and BPD studies announced in September 2026
  • Positive Phase 1 data for XEN1701 (NaV1.7) and XEN1120 (KV7) pain programs; Phase 2 POC studies expected H1 2027
  • Cash, cash equivalents and marketable securities of $1,153.5M as of September 30, 2026; cash runway into 2029
  • Q3 2026 net loss of $110.4M vs $90.9M in Q3 2025; R&D expenses $95.6M vs $77.1M
  • Net loss per share of $(1.11) for Q3 2026 vs $(1.15) in Q3 2025

Financial Impact

Q3 2026 net loss $110.4M, wider than $90.9M in Q3 2025; cash position $1.15B provides runway into 2029

net lossR&D expensescash position

Risk Factors

  • Voluntary pause on new enrollment in Phase 3 MDD and BPD studies could signal undisclosed safety or efficacy concerns
  • Pre-revenue biotech with widening net losses; no approved products or revenue stream
  • NDA review outcome for azetukalner is uncertain; any FDA delays or rejections would be materially negative

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-453521
Document: xene-20261109.htm0001193125-26-453521
Document: 0001193125-26-453521-index-headers.html0001193125-26-453521
Document: 0001193125-26-453521-index.html0001193125-26-453521
Document: 0001193125-26-453521.txt0001193125-26-453521
8-K Data (Synthetic)0001193125-26-453521

Track record

19 reports on XENE

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Viewing Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 8h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026